HHHai-Tao Hu

Hai-Tao Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hai-Tao Hu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Xinxin Shao

    Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    2 shared publications
  • Yantao Tian

    Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    2 shared publications
  • Bingzhi Wang

    Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

    1 shared publication
  • Deng-Feng Li

    Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

    1 shared publication
  • Haikuo Wang

    Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    1 shared publication
  • Jianping Xiong

    Department of Interventional Radiology and Vascular Surgery, Peking University Third Hospital, Beijing, China

    1 shared publication

Latest Publications

  • Open Access

    Is Proximal Gastrectomy Oncologically Justifiable for Advanced Siewert II/III Adenocarcinoma of the Esophagogastric Junction?

    by Haikuo Wang, Zhibin Ye, Yiming Lu, Haitao Hu, Yujuan Jiang, Wangyao Li, Xinxin Shao, Yantao Tian

    Wang H, et al. J Gastric Cancer. 2025 Sep;25:e40. https://doi.org/10.5230/jgc.2025.25.e40


  • Open Access

    Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy?

    by Wen-Zhe Kang, Bing-Zhi Wang, Deng-Feng Li, Zhi-Chao Jiang, Jian-Ping Xiong, Yang Li, Peng Jin, Xin-Xin Shao, Hai-Tao Hu, Yan-Tao Tian

    A high Mandard score may indicate the tumor is insensitive to chemotherapy. We analyzed tumor regression and lymph node response under different Mandard scores to assess the impact of Mandard score on prognosis. Methods. Mandard scores and ypN stage of postoperative pathological reports were recorded. The results were reviewed by a professional pathologist. The radiologist compared the tumor regression before and after chemotherapy by computed tomography (CT). The survival of all patients was obtained by telephone follow-up. Multivariate Cox regression was used to assess the relationship between overall risk of death and Mandard score, imaging evaluation, and ypN stage. Results. In the Mandard score (4-5) group, the median survival time for PR and ypN0 patients was 68.5 and 76.7 months. While in the Mandard score (1-2) group, the median survival time for PD and ypN3a patients was 15.6 and 14.5 months. Imaging evaluation of tumor regression (PR 68.5 months, SD 27.8 months, and PD 10.2 months) and lymph node remission (ypN0 76.7 months, ypN1 61.6 months, ypN2 18.0 months, ypN3a 18.7 months, and ypN3b 18.3 months) showed improved survival. Mandard score, imaging evaluation, and ypN stage are important prognostic factors affecting prognosis. Conclusion. A high Mandard score does not mean neoadjuvant chemotherapy is ineffective in gastric cancer. Patients with imaging evaluation of tumor regression and ypN stage reduction may benefit from neoadjuvant chemotherapy.